The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment, yet their efficacy in breast cancer remains limited to subsets of triple-negative breast cancer (TNBC) with PD-L1 positivity or high tumor-infiltrating lymphocytes (TILs) (9). This evidence concerns the gene CD274 and breast carcinoma.